Fertility and Sterility
Volume 89, Issue 5 , Pages 1221-1228 , May 2008

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

  • Åsa Lindholm, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Sunderby Hospital, Luleå, Sweden
    • Corresponding Author InformationReprint requests: Åsa Lindholm, M.D., Department of Obstetrics and Gynecology, Sunderby Hospital, 971 80 Luleå, Sweden (Fax: +46 920 211801).
    • ,
  • Marie Bixo, M.D., Ph.D.

      Affiliations

    • Department of Clinical Science, Obstetrics and Gynecology, University Hospital, Umeå, Sweden
    • ,
  • Inger Björn, M.D., Ph.D.

      Affiliations

    • Department of Clinical Science, Obstetrics and Gynecology, University Hospital, Umeå, Sweden
    • Läkarhuset Björnen, Piteå, Sweden
    • ,
  • Pål Wölner-Hanssen, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden
    • ,
  • Mats Eliasson, M.D., Ph.D.

      Affiliations

    • Department of Internal Medicine, Sunderby Hospital, Luleå, Sweden
    • ,
  • Anders Larsson, M.D., Ph.D.

      Affiliations

    • Department of Clinical Chemistry, University Hospital, Uppsala, Sweden
    • ,
  • Owe Johnson, M.D., Ph.D.

      Affiliations

    • Department of Internal Medicine, University Hospital, Umeå, Sweden
    • ,
  • Inger Sundström Poromaa, M.D., Ph.D.

      Affiliations

    • Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

Received 18 January 2007 ,Revised 28 March 2007 ,Accepted 1 May 2007.

References 

  1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011
  2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749
  3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438
  4. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71:599–604
  5. Dahlgren E, Johansson S, Lindstedt G, Knutson F, Oden A, Janson PO. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992;57:505–513
  6. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willet WC, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87:2013–2017
  7. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–146
  8. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169
  9. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid artery haemodynamics in women with polycystic ovaries. Clin Sci (Lond). 2000;98:661–665
  10. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet. 2000;356:1166–1167
  11. Lakhani K, Seifalian AM, Hardiman P. Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation. 2002;106:81–85
  12. Macut D, Micic D, Cvijovic G, Sumarac M, Kendereski A, Zoric S, et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab. 2001;14(Suppl 5):1353–1359
  13. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf). 1993;39:1–16
  14. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf). 1994;41:463–471
  15. Robinson S, Henderson AD, Gelding SV, Kiddy G, Niththyananthan R, Bush A, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 1996;44:277–284
  16. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946–951
  17. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril. 1998;69:236–241
  18. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1996;45:623–629
  19. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?. Hum Reprod. 1996;11:23–28
  20. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:2586–2593
  21. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470–1474
  22. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;CD003053
  23. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21:80–89
  24. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome—a randomised, double-blind, placebo-controlled trial. BJOG. 2006;113:817–824
  25. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999;33:968–978
  26. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–2120
  27. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145:81–90
  28. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316
  29. Mathus-Vliegen EM. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr. 2005;59(Suppl 1):S31–S38
  30. Redmon JB, Reck KP, Raatz SK, Swanson JE, Kwong CA, Ji H, et al. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care. 2005;28:1311–1315
  31. Lazurova I, Dravecka I, Kraus V, Petrovicova J. Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. Bratisl Lek Listy. 2004;105:207–210
  32. Sabuncu T, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril. 2003;80:1199–1204
  33. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91:4842–4848
  34. Gennarelli G, Holte J, Berglund L, Berne C, Massobrio M, Lithell H. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod. 2000;15:2098–2102
  35. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia. 2000;43:1507–1511
  36. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21:457–468
  37. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003;60:1109–1116
  38. Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod. 1997;12(Suppl 1):82–87
  39. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259:493–519
  40. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004;42:1355–1363
  41. Rosner W. Plasma steroid–binding proteins. Endocrinol Metab Clin North Am. 1991;20:697–720
  42. Bataille V, Perret B, Evans A, Amouyel P, Arveiler D, Ducimetiere P, et al. Sex hormone–binding globulin is a major determinant of the lipid profile: the PRIME study. Atherosclerosis. 2005;179:369–373
  43. Preziosi P, Barrett-Connor E, Papoz L, Roger M, Saint-Paul M, Nahoul K, et al. Interrelation between plasma sex hormone–binding globulin and plasma insulin in healthy adult women: the telecom study. J Clin Endocrinol Metab. 1993;76:283–287
  44. Larsson A. Cystatin C: an emerging glomerular filtration rate marker. Scand J Clin Lab Invest. 2005;65:89–91
  45. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–246
  46. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060
  47. Larsson A, Helmersson J, Hansson LO, Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest. 2005;65:301–305
  48. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;CD004094
  49. De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Early first-trimester sibutramine exposure: pregnancy outcome and neonatal follow-up. Drug Saf. 2006;29:255–259
  50. Einarson A, Bonari L, Sarkar M, McKenna K, Koren G. Exposure to sibutramine during pregnancy: a case series. Eur J Obstet Gynecol Reprod Biol. 2004;116:112
  51. Kadioglu M, Ulku C, Yaris F, Kesim M, Kalyoncu NI, Yaris E. Sibutramine use in pregnancy: report of two cases. Birth Defects Res A Clin Mol Teratol. 2004;70:545–546
  52. Ramzi F, Elias D, Mona S, Zreik TG. Sibutramine in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;122:243–244
  53. Morrison JL, Riggs KW, Rurak DW. Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev. 2005;17:641–650
  54. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs. 2005;19:623–633
  55. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf. 2005;28:565–581

 Supported by grants from the Family Planning Foundation, Utvecklingsfonden Uppsala University Hospital, Visare Norr, and by a small grant (20000 SEK) from Abbott Scandinavia AB. Abbott Scandinavia AB had no influence on the planning or completing the study, nor any influence on how data were analyzed or presented. Abbott Scandinavia AB had no access to the data.

PII: S0015-0282(07)01029-1

doi: 10.1016/j.fertnstert.2007.05.002

Fertility and Sterility
Volume 89, Issue 5 , Pages 1221-1228 , May 2008

Article Tools

* Image Usage & Resolution